
Novo Nordisk Plans Price Cuts for Several Insulins

Novo Nordisk will start slashing some U.S. insulin prices up to 75% next year, following a path set earlier this month by rival Eli Lilly.
The Danish drugmaker said Tuesday that pre-filled pens and vials of long- and short-acting insulins will see list price reductions. They include Levemir, Novolin, NovoLog and NovoLog Mix70/30.
Novo also will drop the list price of unbranded products like Insulin Aspart to match the lower price of the branded insulins.
The price cuts go into effect Jan. 1. A vial of NovoLog and NovoLog Mix 70/30 will drop 75% to $72.34 from $289.36. FlexPen options will fall to $139.71 from more than $500.
Levemir and Novolin vials and FlexPens will drop 65% from their current list prices.
Eli Lilly and Co. said March 2 that it will cut the list prices for its most commonly prescribed insulin, Humalog, and for another insulin, Humulin, by 70% or more in the fourth quarter, which starts in October.
List prices are what a drugmaker initially sets for a product and what people who have no insurance or plans with high deductibles are sometimes stuck paying.
Patient advocates have long called for insulin price cuts to help uninsured people who would not be affected by price caps tied to insurance coverage. They have noted that high insulin prices force many people to ration doses, which can be dangerous for their health.
Research has shown that prices for insulin have more than tripled in the last two decades. Pressure is growing on drugmakers to help patients.
Major insulin makers like Lilly and Novo have said they offer patient assistance programs and other help. But Lilly CEO David Ricks noted earlier this month that discounts the drugmaker offers from its list prices often don’t reach patients through insurers or pharmacy benefit managers.
The federal government in January started applying a $35 cap on monthly out-of-pocket costs to patients with coverage through its Medicare program for people age 65 and older or those who have certain disabilities or illnesses.
Insulin is made by the pancreas and used by the body to convert food into energy. People who have diabetes don’t produce enough insulin. Those with Type 1 diabetes must take insulin every day to survive.
More than 8 million Americans use insulin, according to the American Diabetes Association.
The Wall Street Journal first reported the price cuts Tuesday morning.
In The News
Health
Voting
Health
RALEIGH, N.C. (AP) — A Medicaid expansion deal in North Carolina received final legislative approval on Thursday, ending a decade of debate... Read More
RALEIGH, N.C. (AP) — A Medicaid expansion deal in North Carolina received final legislative approval on Thursday, ending a decade of debate over whether the closely politically divided state should accept the federal government's coverage for hundreds of thousands of low-income adults. North Carolina is one of several... Read More
WASHINGTON — The chief executive of Moderna Inc. defended his plan to quadruple the price of the COVID-19 vaccine during... Read More
WASHINGTON — The chief executive of Moderna Inc. defended his plan to quadruple the price of the COVID-19 vaccine during a Senate hearing Wednesday by saying his company is preparing for a sharp decline in demand. With as much as a 90% drop in customers as... Read More
NEW YORK (AP) — Nearly 200 years after Ludwig van Beethoven's death, researchers pulled DNA from strands of his hair,... Read More
NEW YORK (AP) — Nearly 200 years after Ludwig van Beethoven's death, researchers pulled DNA from strands of his hair, searching for clues about the health problems and hearing loss that plagued him. They weren't able to crack the case of the German composer's deafness or... Read More
NEW YORK (AP) — U.S. cases of a dangerous fungus tripled over just three years, and more than half of... Read More
NEW YORK (AP) — U.S. cases of a dangerous fungus tripled over just three years, and more than half of states have now reported it, according to a new study. The COVID-19 pandemic likely drove part of the increase, researchers at the Centers for Disease Control... Read More
WASHINGTON — A week after the House overwhelmingly voted to declassify any and all information related to the origin of... Read More
WASHINGTON — A week after the House overwhelmingly voted to declassify any and all information related to the origin of COVID-19, President Joe Biden signed the measure into law, saying, “I share the Congress’ goal of releasing as much information as possible” about the virus. The... Read More
BOSTON — Encouraged by positive topline results from its phase 3 trial for its new therapy for adults with schizophrenia,... Read More
BOSTON — Encouraged by positive topline results from its phase 3 trial for its new therapy for adults with schizophrenia, Karuna Therapeutics announced Monday that it is on track to submit KarXT to the Food and Drug Administration for approval by summer. If that comes to... Read More